What is the prevalence of Pulmonary Hypertension?

TL;DR: Pulmonary Hypertension (PH) is a complex condition with a prevalence estimated between 10 and 50 per million people, though these figures vary significantly by subtype and diagnostic criteria. While it is classified as a rare disease, the true global prevalence of Pulmonary Hypertension remains difficult to track due to frequent underdiagnosis and its classification as a secondary complication of other heart and lung disorders.

What is the estimated prevalence and incidence of Pulmonary Hypertension?

Estimating the exact number of people living with Pulmonary Hypertension is challenging because the condition is often secondary to other diseases. According to Orphanet, the prevalence of idiopathic pulmonary arterial hypertension (IPAH)—a specific form of the disease—is estimated at approximately 2 to 6 per million in the general population. However, when considering all forms of Pulmonary Hypertension, including those secondary to left heart disease or chronic lung disease, the numbers are substantially higher. Incidence rates for IPAH are estimated at 1 to 2 new cases per million people per year, but these figures are highly sensitive to the diagnostic screening protocols used in different clinical settings.

Does Pulmonary Hypertension affect specific groups differently?

The demographic distribution of Pulmonary Hypertension shows distinct patterns that clinicians monitor closely:

• Gender Distribution: Many forms of Pulmonary Hypertension, particularly idiopathic PAH, are diagnosed more frequently in females than in males, with some studies suggesting a ratio of nearly 2:1 or even higher.


• Age of Onset: While Pulmonary Hypertension can affect individuals of any age, it is most commonly diagnosed in adults between the ages of 30 and 60. Pediatric cases exist but are often associated with congenital heart defects or developmental lung issues.


• Geographic and Ethnic Variations: Data suggests that certain genetic predispositions and environmental factors (such as high altitude or exposure to specific toxins) can influence regional prevalence rates, though large-scale global ethnic studies are still evolving.

Why is it difficult to determine the exact prevalence of Pulmonary Hypertension?

Accurate epidemiological data for Pulmonary Hypertension is hindered by the "silent" nature of early symptoms, such as unexplained shortness of breath or fatigue, which are often attributed to more common conditions like asthma or aging. Many patients live with symptoms for months or years before receiving a definitive diagnosis via right heart catheterization. At DiseaseMaps.org, we have seen 101 members join our community to share their experiences with Pulmonary Hypertension, providing a vital real-world perspective that highlights the diagnostic delays many patients face before they are correctly mapped and treated.

Is Pulmonary Hypertension considered a rare disease?

Yes, most clinical definitions classify Pulmonary Hypertension, specifically the arterial forms (PAH), as a rare disease. Because it is a progressive condition requiring specialized care from pulmonary hypertension centers, early identification is essential for managing prognosis and quality of life. The 101 individuals currently in the DiseaseMaps.org community represent a small fraction of the global population, underscoring the importance of patient registries in better understanding the true scope of this condition.

Next steps

• Consult a board-certified pulmonologist or cardiologist who specializes in Pulmonary Hypertension to ensure an accurate diagnosis.


• Request a referral to an accredited Pulmonary Hypertension Care Center for access to the latest clinical trials and therapies.


• Join the community at DiseaseMaps.org to connect with others, share your journey, and stay informed about the latest research updates.


• Keep a symptom log to track your health progress, which can provide your medical team with valuable data during consultations.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• Orphanet: Pulmonary arterial hypertension (ORPHA:423).


• NIH Genetic and Rare Diseases Information Center (GARD): Pulmonary hypertension.


• Pulmonary Hypertension Association (PHA): Understanding PH statistics and patient resources.


• Journal of the American College of Cardiology: Global epidemiology of pulmonary hypertension.